- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03840824
Blood Spot Self-administered Test and Assay
Přehled studie
Postavení
Detailní popis
Recent advances in cancer diagnosis and treatment have led to greater survival rates in patients with malignancies. However, these life-saving treatments, especially alkylating agents, often lead to premature ovarian failure, infertility and related long-term health problems. It is difficult to predict whether, and the extent to which, patients will experience these problems. There are no early clinical signs of decreased fertility potential; even young women who maintain cyclic menses after therapy are at high risk of infertility, early menopause and related health problems. Preliminary studies suggest that several surrogate measures of fertility potential are different in cancer survivors compared with controls. These include follicle stimulating hormone (FSH), estradiol, anti-mullerian hormone (AMH) and inhibin B. Large longitudinal studies are needed to validate these measures with gold standard outcomes such as pregnancy rates, pregnancy outcomes and time to menopause. The main impediment to assessing the value of these markers and generating data that is useful to cancer survivors is the need for frequent and timed blood samples.
Daily or frequent trips to the clinical center are not practical and reduce the compliance of even the most motivated patients. The hypothesis that will be tested by this study is that blood spot assays can be developed that provide robust, personalized data for surrogate markers of reproductive function which can be used to assess reproductive potential in women; furthermore, bloodspots collected at home are an acceptable method for reproductive hormone measurement in women with and without a history of cancer. The current study will compare hormone levels of AMH, FSH and inhibin B in blood specimens collected by venipuncture and fingerstick in a sample of subjects.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19143
- University of Pennsylvania, Reproductive Research Unit
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
The target population is 80 pre-menopausal women ages 18-45 years with normal menstrual cycles:
Aim 1: Total 80 subjects:
- 30 cancer survivors
- 30 similar aged healthy controls
- 20 late reproductive aged women
Aim 2: Subset of 60 subjects:
- 30 cancer survivors
- 30 similar aged healthy controls
Popis
Inclusion Criteria:
- Adult females
- Age between 18-45 years
- Premenopausal (defined as menses in the past 12 months)
- Postmenarchal
- Presence of an intact uterus and two ovaries
- Ability and willingness to comply with study protocol
Exclusion Criteria:
- Pregnancy within the previous 3 months
- Lactation within the previous 3 months
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
---|
Cancer Survivor
Pre-menopausal women who are cancer survivors ages 18-45 years with normal menstrual cycles.
|
Similar aged healthy controls
Pre-menopausal, healthy women ages 18-45 years with normal menstrual cycles
|
Late Reproductive Age
Pre-menopausal, healthy women of late reproductive age
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
AMH pg/mL in dried bloodspot vs serum samples
Časové okno: Day 1
|
Serum AMH ELISA assay results will be compared to capillary blood sample AMH collected on filter paper and dried.
Recovery of spiked ligands, sensitivity and specificity of the assays will be also assessed.
|
Day 1
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Adequacy of subject's self-collected bloodspot sample vs. sample collected in clinic
Časové okno: Day 1
|
A capillary blood sample from a finger-prick is applied to Whatman #903 filter paper, allowed to dry at room temperature for at least 4 hours, and then stored until analysis in the laboratory.
Subjects willing to conduct a finger stick at home will collect an additional dried blood spot sample for secondary outcome measures.
At home blood spot cards will be compared to those obtained in the office to determine adequacy of collection.
|
Day 1
|
Measures of user acceptability through subject report/feedback
Časové okno: Day 1
|
Ease of use data reported by subject survey will be summarized to determine the overall acceptability of bloodspot collection and the potential for at- home use
|
Day 1
|
AMH pg/mL in cancer survivors vs. healthy control cohorts
Časové okno: Day 1
|
AMH in dried blood spots vs. serum collected during the early follicular phase in 30 cancer survivors (15 exposed to low dose cancer therapy, 15 exposed to high dose cancer therapy) and 30 healthy similar aged controls will be compared using tests and multivariable linear regression
|
Day 1
|
FSH (mIU/mL) in dried bloodspot vs serum samples
Časové okno: Day 1
|
Serum FSH ELISA assay results will be compared to FSH in a dried capillary blood sample applied to filter paper.
Recovery of spiked ligands and sensitivity and specificity of the assays will be assessed.
|
Day 1
|
Inhibin B (pg/ml) in dried bloodspot vs serum samples
Časové okno: Day 1
|
Serum Inhibin B ELISA assay results will be compared to capillary blood sample Inhibin B collected on filter paper and dried.
Recovery of spiked ligands and sensitivity and specificity of the assays will be assessed.
|
Day 1
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Clarisa Gracia, MD, MSCE, University of Pennsylvania
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 812735
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Účinky chemoterapie
-
PepsiCo Global R&DDokončenoDovednostní výkon | Fotbalový výkon | Coffeeberry EffectsSpojené království
-
PepsiCo Global R&DDokončenoDovednostní výkon | Fotbalový výkon | Coffeeberry EffectsSpojené království
-
Northwestern UniversityUniversity of Wisconsin, StoutDokončenoPerception of Skin of Color Clinics u AfroameričanůSpojené státy
-
Sisli Hamidiye Etfal Training and Research HospitalDokončeno
-
Sorbonne UniversityAalborg UniversityNáborPoint of Care ultrazvukFrancie
-
Imperial College LondonDokončenoProof Of Concept StudieSpojené království
-
Asociacion Española Primera en SaludIntensive Care Unit Pasteur HospitalDokončenoPoint of Care ultrazvukUruguay
-
Aga Khan UniversityThe Hospital for Sick Children; Grand Challenges CanadaNeznámýPoint of Care ultrazvukPákistán
-
Research Unit Of General Practice, CopenhagenUniversity of Copenhagen; Region Capital Denmark; The Copenhagen General Practice... a další spolupracovníciDokončeno
-
Research Unit Of General Practice, CopenhagenUniversity of Copenhagen; Region Capital Denmark; The Copenhagen General Practice... a další spolupracovníciDokončeno